 | Up a level |
Journal Article
Baues, C., Semrau, R., Gaipl, U. S., Broeckelmann, P. J., Rosenbrock, J., Engert, A. and Marnitz, S. (2017). Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma. Strahlenther. Onkol., 193 (2). S. 95 - 100. MUNICH: URBAN & VOGEL. ISSN 1439-099X
Borchmann, P., Kobe, C., Pluetschow, A., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Soekler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Huettmann, A., Wilhem, M., Zijlstra, J. M., Moccia, A., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Eich, H., Baues, C., Hallek, M., Diehl, V, Dietlein, M. and Engert, A. (2020). Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group. Oncol. Res. Treat., 43 (SUPPL 4). S. 32 - 33. BASEL: KARGER. ISSN 2296-5262
Borchmann, S., Goergen, H., Sasse, S., Kreissl, S., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Diehl, V. and Engert, A. (2018). Pretreatment vitamin D deficiency is associated with lower progression free and overall survival in prospectively treated Hodgkin lymphoma. Oncol. Res. Treat., 41. S. 273 - 275. BASEL: KARGER. ISSN 2296-5262
Broeckelmann, P. J., Byrne, K., Hallworth, P., Blackburn, S., Kupas, K., Juarez-Garcia, A. and Chen, C. (2018). Current later-line drug treatment patterns of patients with classical Hodgkin lymphoma (cHL) in Germany. Oncol. Res. Treat., 41. S. 113 - 114. BASEL: KARGER. ISSN 2296-5262
Broeckelmann, P. J., Goergen, H., Fuchs, M., Eich, H. T., Stein, H., Diehl, V., Borchmann, P. and Engert, A. (2016). Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: Experience of the German Hodgkin Study Group (GHSG). Oncol. Res. Treat., 39. S. 122 - 123. BASEL: KARGER. ISSN 2296-5262
Broeckelmann, P. J., Goergen, H., Kohnhorst, C., Fuchs, M., Borchmann, P. and Engert, A. (2016). VERY LATE RELAPSE > 5 YEARS AFTER FIRST DIAGNOSIS OF HODGKIN LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP HD7-HD12 TRIALS. Haematologica, 101. S. 46 - 48. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Broeckelmann, P. J., Goergen, H., Kohnhorst, C., Fuchs, M., Borchmann, P. and Engert, A. (2016). VERY LATE RELAPSE > 5 YEARS AFTER FIRST DIAGNOSIS OF HODGKIN LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP HD7-HD12 TRIALS. Haematologica, 101. S. 320 - 321. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Broeckelmann, P. J., Goergen, H., Pluetschow, A., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE HODGKIN LYMPHOMA (HL): UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD7, HD8, HD10 AND HD11 TRIALS. Haematologica, 101. S. 4 - 5. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Broeckelmann, P. J., Mueller, H., Casasnovas, O., Hutchings, M., von Tresckow, B., Jurgens, M., McCall, S. J., Morschhauser, F., Fuchs, M., Borchmann, P., Moskowitz, C. H. and Engert, A. (2017). Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann. Oncol., 28 (6). S. 1352 - 1359. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Broeckelmann, P. J., Mueller, H., Kuecueksarioglan, E., Engert, A. and von Tresckow, B. (2017). DISEASE CHARACTERISTICS AND SURVIVAL AFTER 3RD RECURRENCE OF CLASSICAL HODGKIN LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP. Haematologica, 102. S. 146 - 147. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Broeckelmann, P. J., Zagadailov, E. A., Corman, S., Hagan, M., Chirikov, V., Johnson, C., Macahilig, C. and Dalal, M. R. (2016). BRENTUXIMAB VEDOTIN (BV) IN PATIENTS WHO ARE INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (RRHL): A UK AND GERMANY RETROSPECTIVE STUDY. Haematologica, 101. S. 98 - 99. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Broeckelmann, P. J., Zagadailov, E. A., Corman, S., Hagan, M., Chirikov, V., Johnson, C., Macahilig, C., Seal, B., Dalal, M. R. and Illidge, T. (2016). BRENTUXIMAB VEDOTIN IN PATIENTS WHO ARE INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: A UNITED KINGDOM AND GERMANY RETROSPECTIVE STUDY. Haematologica, 101. S. 50 - 52. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Buerkle, C., Goergen, H., Mueller, H., Broeckelmann, P. J., Kreissl, S., Fuchs, M., Engert, A., Borchmann, P. and Behringer, K. (2016). PATIENT PREFERENCES - SURVEY OF HL SURVIVORS ON TREATMENT-ASSOCIATED BURDENS AND SIDE EFFECTS. Haematologica, 101. S. 61 - 62. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Eichenauer, D. A., Goergen, H., Pluetschow, A., Wongso, D., Behringer, K., Kreissl, S., Thielen, I., Halbsguth, T., Broeckelmann, P. J., Fuchs, M., Boell, B., von Tresckow, B., Borchmann, P. and Engert, A. (2016). Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. Leukemia, 30 (6). S. 1425 - 1429. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Hude, I., Sasse, S., Broeckelmann, P. J., von Tresckow, B., Momotow, J., Engert, A. and Borchmann, S. (2017). BASELINE LEUKOCYTE AND EOSINOPHIL COUNTS PREDICT OUTCOME IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS TREATED WITH PD1 INHIBITION. Haematologica, 102. S. 460 - 461. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Jakob, T., Follmann, M., Borchmann, P., Baues, C., Sasse, S., Broeckelmann, P. J., Kreissl, S., Eichenauer, D., von Tresckow, B., Buerkle, C., Engert, A. and Skoetz, N. (2018). Guideline update on diagnosis, therapy and follow-up of adult Hodgkin lymphoma patients. Oncol. Res. Treat., 41. S. 17 - 18. BASEL: KARGER. ISSN 2296-5262
Kobe, C., Kuhnert, G., Haverkamp, H., Fuchs, M., Kahraman, D., Eich, H. -T., Kriz, J., Baues, C., Nast-Kolb, B., Broeckelmann, P. J., Borchmann, P., Drzezga, A., Engert, A. and Dietlein, M. (2015). Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma. Nuklearmedizin, 54 (6). S. 241 - 247. STUTTGART: GEORG THIEME VERLAG KG. ISSN 2567-6407
Kramer, R., Mentzer, D., Erdmann, M., Knauss, S., Broeckelmann, P. J., Hassel, J. C., Ugurel, S., Pavel, M., Nickel, F. T., Landendinger, M., Fuchs, F., Meidenbauer, N., Jefremow, A., Manger, B., Gutzmer, R., Loquai, C., Kaehler, K., Zimmer, L., Berking, C., Keller-Stanislawski, B. and Heinzerling, L. (2020). SERIO - Side Effect Registry Immuno-Oncology Side Effect Registry for rare, severe and complex Side Effects of Immunotherapy. J. Dtsch. Dermatol. Ges., 18. S. 14 - 16. HOBOKEN: WILEY. ISSN 1610-0387
Pauls, K. A. M., Broeckelmann, P. J., Hammesfahr, S., Becker, J., Hellerbach, A., Visser-Vandewalle, V., Dembek, T. A., Meister, I. G. and Timmermann, L. (2018). Dysarthria in pallidal Deep Brain Stimulation in dystonia depends on the posterior location of active electrode contacts: a pilot study. Parkinsonism Relat. Disord., 47. S. 71 - 76. OXFORD: ELSEVIER SCI LTD. ISSN 1873-5126
Sasse, S., Broeckelmann, P. J., Baues, C., Eich, H. T. and Engert, A. (2018). Treatment of early stage Hodgkin lymphoma. Discussion of current trials and treatment recommendations. Onkologe, 24 (4). S. 303 - 315. NEW YORK: SPRINGER. ISSN 1433-0415
Sasse, S., Broeckelmann, P. J., Goergen, H., Pluetschow, A., Mueller, H., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD7 AND HD10 TRIAL. Haematologica, 101. S. 12 - 13. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Sasse, S., Broeckelmann, P. J., Goergen, H., Pluetschow, A., Mueller, H., Kreissl, S., Buerkle, C., Borchmann, S., Fuchs, M., Borchmann, P. and Engert, A. (2016). LONG-TERM FOLLOW-UP OF CONTEMPORARY TREATMENT IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: UPDATED ANALYSES OF THE GERMAN HODGKIN STUDY GROUP HD8 AND HD11 TRIAL. Haematologica, 101. S. 13 - 15. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Sasse, S., Momotow, J., Broeckelmann, P. J., Baues, C., Eich, H. T. and Engert, A. (2022). Treatment of early stage favorable and unfavorable Hodgkin lymphoma. Onkologie, 28 (10). S. 879 - 889. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234
Tometten, L., Malin, J. J., Pracht, E., Broeckelmann, P. J., Horn, C., Sprute, R., Langhorst, C. A., Hallek, M., Faetkenheuer, G. and Rybniker, J. (2023). Recurrent SARS-CoV-2 infections in immunodeficiency. Innere Med., 64 (1). S. 84 - 88. Berlin: SPRINGER MEDIZIN. ISSN 2731-7099
Vehreschild, J. J., Broeckelmann, P. J., Bangard, C., Verheyen, J., Vehreschild, M. J. G. T., Michels, G., Wisplinghoff, H. and Cornely, O. A. (2012). Pandemic 2009 influenza A(H1N1) virus infection coinciding with invasive pulmonary aspergillosis in neutropenic patients. Epidemiol. Infect., 140 (10). S. 1848 - 1853. NEW YORK: CAMBRIDGE UNIV PRESS. ISSN 1469-4409
Zagadailov, E. A., Corman, S., Hagan, M., Chirikov, V., Johnson, C., Macahilig, C., Dalal, M. R. and Broeckelmann, P. J. (2016). REAL-WORLD EFFECTIVENESS OF BRENTUXIMAB VEDOTIN (BV) VS OTHER TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (RRHL) POST AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT). Haematologica, 101. S. 98 - 100. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Zagadailov, E. A., Corman, S., Hagan, M., Chirikov, V., Johnson, C., Macahilig, C., Dalal, M. R. and Broeckelmann, P. J. (2016). RISK FACTORS (RF) FOR RELAPSE IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (RRHL) AFTER AUTOLOGOUS STEM CELL TRANSPLANT (ASCT): A REAL-WORLD ANALYSIS IN GERMANY AND THE UNITED KINGDOM (UK). Haematologica, 101. S. 98 - 99. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Zagadailov, E. A., Corman, S., Hagan, M., Chirikov, V., Johnson, C., Macahilig, C., Sea, B., Dalal, M. R., Broeckelmann, P. J. and Illidge, T. (2016). REAL-WORLD EFFECTIVENESS OF BRENTUXIMAB VEDOTIN VS OTHER TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA POST AUTOLOGOUS STEM-CELL TRANSPLANTATION. Haematologica, 101. S. 51 - 52. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Zagadailov, E. A., Corman, S., Hagan, M., Chirikov, V., Johnson, C., Macahilig, C., Seal, B., Dalal, M. R., Illidge, T. and Broeckelmann, P. J. (2016). RISK FACTORS FOR RELAPSE IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A REAL-WORLD ANALYSIS IN GERMANY AND THE UNITED KINGDOM. Haematologica, 101. S. 51 - 53. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078